Intravenous Chlorpromazine as Potentially Useful Treatment for Chronic Headache Disorders.

Autor: Ruiz Yanzi MA; Department of Neurology, Fleni, Buenos Aires, Argentina., Goicochea MT; Headache Section, Department of Neurology, Fleni, Buenos Aires, Argentina., Yorio F; Department of Neurology, Fleni, Buenos Aires, Argentina., Alessandro L; Department of Neurology, Fleni, Buenos Aires, Argentina., Farez MF; Center for Biostatistics, Epidemiology and Public Health (CEBES), Fleni, Buenos Aires, Argentina., Marrodan M; Department of Neurology, Fleni, Buenos Aires, Argentina.
Jazyk: angličtina
Zdroj: Headache [Headache] 2020 Nov; Vol. 60 (10), pp. 2530-2536. Date of Electronic Publication: 2020 Sep 26.
DOI: 10.1111/head.13976
Abstrakt: Objective: The aim of this study was to describe a group of patients with chronic headache disorders (CH) and medication overuse headache (MOH) treated with intravenous chlorpromazine (IVC). We hypothesized that IVC is an effective and safe addition to well-known treatment strategies for CH and MOH management.
Introduction: Up to 4% of the general population could experience CH. Most cases occur in women, in association with MOH. To date, evidence to support different treatment strategies is lacking. Although IVC is frequently used in the emergency room (ER), documentation on its use as supportive treatment for CH and for withdrawal management of MOH is poor.
Methods: A retrospective cohort of patients hospitalized to receive treatment for CH in a specialized neurological center in Argentina was analyzed.
Results: A total of 35 CH patients were included. Of the 35 patients, 33 (94%) patients also presented MOH. Patients reported only minor side effects to IVC administration (mainly drowsiness and symptomatic hypotension). Three months after inpatient treatment, the number of ER visits made by these patients decreased from an average of 2.8 in the 3 months prior to hospitalization to 0.7 after it (72%, P = .009). Headache frequency decreased in 20/34 (59%) patients during the same time period. Pain levels had dropped from a mean of 8 points at admission (in the scale of 1-10) to 2 points at discharge. In the first 3 months of follow-up, the average number of days per month in which patients experienced headache decreased from 28.9 to 15.4 days (53.3%, P < .0001).
Conclusion: In this particular group of inpatients, there were no significant safety issues with IVC administration and the study might suggest that the efficacy of IVC as an add-on treatment for CH and MOH.
(© 2020 American Headache Society.)
Databáze: MEDLINE
Externí odkaz: